OncoMatch/Clinical Trials/NCT05972135
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Is NCT05972135 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Teclistamab and Talquetamab for multiple myeloma.
Treatment: Teclistamab · Talquetamab · Tocilizumab · Oral Dexamethasone — This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody.
Must have received: immunomodulatory agent
has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody.
Must have received: CD38 antibody
has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody.
Cannot have received: gene modified adoptive cell therapy (CAR-T cells, NK cells, BCMA therapy)
For teclistamab arms only: Prior Gene modified adoptive cell therapy (eg, chimeric antigen receptor modified [CAR]-T cells, NK cells, or BCMA therapy)
Cannot have received: GPRC5D-targeting therapy
For talquetamab arm only: any prior GPRC5D-targeting therapy
Cannot have received: CAR-T cell therapy
For talquetamab arm only: Prior Grade 3 or higher CRS related to any T-cell redirection (e.g., CD-3 redirection technology or CAR-T cell therapy)
Cannot have received: BCMA bispecific antibody
For talquetamab arm only: Prior CAR-T or BCMA bispecific antibody therapy are allowed with the appropriate wash-out period: 1) Gene modified adoptive cell therapy (eg, chimeric antigen receptor modified [CAR]-T cells, NK cells) within 3 months, or 2) BCMA therapies (antibody-drug conjugates and bispecific antibodies, etc) within 21 days or at least 5 half-lives, whichever is less.
Lab requirements
Blood counts
Grade ≥3 hematologic AEs [excluded]
Kidney function
eGFR <20 ml/min or is dependent on dialysis [excluded]
Liver function
Adequate organ system function
Cardiac function
Presence of the following cardiac conditions: NYHA stage III or IV CHF, MI or CABG ≤6 months prior, history of clinically significant ventricular arrhythmia or unexplained syncope, severe non-ischemic cardiomyopathy, poorly controlled CAD and/or CHF, uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities
Adequate organ system function. Has Grade ≥3 hematologic AEs or Grade ≥3, clinically significant non-hematologic AEs. eGFR <20 ml/min or is dependent on dialysis [excluded]. Presence of the following cardiac conditions: New York Heart Association stage III or IV congestive heart failure. Myocardial infarction or CABG ≤6 months prior to enrollment. History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration. History of severe non-ischemic cardiomyopathy. Poorly controlled coronary artery disease and/or congestive heart failure. Uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arizona Oncology Associates · Tucson, Arizona
- Colorado Blood Cancer Institute · Denver, Colorado
- Rocky Mountain Cancer Center · Denver, Colorado
- Medical Oncology Hematology Consultants · Newark, Delaware
- Florida Cancer Specialists · Lake Mary, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify